Leap Therapeutics, Inc.
General ticker "LPTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $34.3M (TTM average)
Leap Therapeutics, Inc. follows the US Stock Market performance with the rate: 26.0%.
Estimated limits based on current volatility of 8.6%: low 0.91$, high 1.09$
Factors to consider:
- Total employees count: 54 (+22.7%) as of 2023
- Top business risk factors: Operational and conduct risks, Funding requirements, Product development risks, Manufacturing risks, Third-party risks
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.77$, 2.34$]
- 2026-12-31 to 2027-12-31 estimated range: [0.60$, 1.79$]
Financial Metrics affecting the LPTX estimates:
- Positive: with PPE of 16.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -57.64 <= 0.07
- Positive: Interest expense per share per price, % of 0.03 <= 0.73
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 2.87
- Positive: Shareholder equity ratio, % of 94.07 > 64.25
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term LPTX quotes
Long-term LPTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $87.04MM | $70.06MM | $36.54MM |
| Operating Income | $-87.04MM | $-70.06MM | $-36.54MM |
| Non-Operating Income | $5.63MM | $3.09MM | $46.62MM |
| Interest Expense | $0.00MM | $0.00MM | $0.02MM |
| R&D Expense | $73.23MM | $57.21MM | $25.67MM |
| Income(Loss) | $-81.41MM | $-66.97MM | $10.08MM |
| Taxes | $0.00MM | $0.58MM | $5.25MM |
| Profit(Loss)* | $-81.41MM | $-67.56MM | $4.82MM |
| Stockholders Equity | $60.14MM | $35.05MM | $153.51MM |
| Assets | $72.83MM | $49.12MM | $163.18MM |
| Operating Cash Flow | $-43.75MM | $-60.30MM | $-43.90MM |
| Investing Cash Flow | $48.97MM | $0.00MM | $-97.00MM |
| Financing Cash Flow | $-0.03MM | $37.18MM | $107.65MM |
| Earnings Per Share** | $-3.98 | $-1.80 | $0.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.